Instrumentation Laboratory Worldwide Sales Top $970 M In 2017
Bedford, MA - May 7, 2018
Instrumentation Laboratory (IL), a Werfen company, announced total worldwide sales in 2017 of $970 M (€862 M), with total growth of 22.2% over 2016, including 6.6% organic growth and 15.6% from corporate acquisitions. In 2017, the Company completed the integration of their Accriva Diagnostics and Tem acquisitions, of January 2017 and September 2016, respectively. IL, an integral part of Werfen, specializes in Hemostasis and Acute Care Diagnostics systems.
In the Hemostasis business line, sales grew 7.5% in local currencies, solidifying the Company’s global leadership position. All key territories contributed, including China with growth of 23.5%, Latin America with 15.2%, and the United States with 8.1%, double that of the market and achieving the #1 market position in the combined North American Hemostasis market.
“2017 was a year of tremendous growth for IL, driven by the outstanding performance of our traditional product lines, as well as the integration of our recent Tem and Accriva acquisitions, which provided us with outstanding new product lines and a team of global experts in Whole Blood Hemostasis and Patient Blood Management,” said Ramon Benet, CEO at IL. “We can now offer an integrated Hemostasis diagnostics system for the laboratory and point-of-care, as well as a comprehensive rapid testing system for a broad range of hospital Acute Care settings, enabling our customers to improve the quality of patient care and experience, while lowering the total cost of care.”
Key Hemostasis achievements in 2017 include continued aggressive growth of the Company’s flagship ACL TOP® Family 50 Series Hemostasis Testing Systems, expansion of the HemoCell™ Specialized Lab Automation customer base, and the addition of important new functionalities for HemoHub™ Intelligent Data Manager. In addition, the Company received 510(k) clearance of the HemosIL® AcuStar HIT-IgG(PF4-H) chemiluminescent assay from the US Food and Drug Administration, complementing the latex-based HemosIL HIT-Ab(PF4-H) assay, and expanding its portfolio for this critically important test.
In Acute Care Diagnostics, the Company integrated its traditional Blood Gas offering with the Whole Blood Hemostasis systems from the Accriva and Tem acquisitions, offering a comprehensive set of products to support Acute Care in clinical hospital settings, from Operating Rooms and Cardiac Catheterization Laboratories, to Emergency Departments and Intensive Care Units. The new Acute Care Diagnostics business line combines the leading GEM Premier™ Blood Gas portfolio with ROTEM Patient Blood Management systems, Hemochron™ anticoagulant testing systems, VerifyNow™ platelet function testing systems, and Avoximeter™ CO-Oximeters. IL also expanded worldwide commercialization of its breakthrough GEM Premier 5000 analyzer with Intelligent Quality Management 2 (iQM2), and launched GEMweb Plus 500 Custom Connectivity, for complete control of GEM Premier systems.